Endo Pharmaceuticals CFO Resigns
Posted on: Thursday, 4 September 2008, 12:00 CDT
Endo Pharmaceuticals, which engages in the research, development, sale and marketing of branded and generic prescription pharmaceuticals, has announced that executive vice president and CFO, Charles Rowland, Jr, has resigned effective immediately, to pursue other interests.
Endo Pharmaceuticals has engaged an executive search firm to assist in the search for a new CFO.
David Holveck, president and CEO of Endo Pharmaceuticals, said: "The board and I wish to express our gratitude to Charlie for his contributions and service and wish him well in his future endeavors."
Source: Datamonitor
Related Articles
- Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
- Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
- Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
- Noven to Present at UBS Global Specialty Pharmaceuticals Conference
- Specialty Pharmaceuticals Business Development and Investor Conference to Take Place May 23-24, 2006, New Brunswick, NJ
- Trading in Noven Common Stock Halted; FDA Advisory Committee Meeting Today on Daytrana(TM)
- Noven Announces Availability of Briefing Documents for Daytrana(TM) Advisory Committee Meeting
- Developmental Methylphenidate Patch Scheduled for FDA Advisory Committee Review
- Noven to Present at Banc of America Securities Specialty Pharmaceuticals Conference
- Shire and Noven Announce Positive Clinical Data for Transdermal ADHD Treatment
Rating: 3.0 / 5 (7 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds